Floatz logo

Tilmanocept

Liver Metastases

Navidea BiopharmaceuticalsOtherPhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
73/ 100

Competitive context

36 Active assets in the Liver Metastases cohort.

Asset / SponsorPhaseRating
Eloxatin
Sun Yat-sen University
Phase 3BB
Irinotecan
Kamya Sankar
Phase 3BB
Calcium folinate pentahydrate
Fudan University
Phase 3BB
FLUOROURACILUM
Sun Yat-sen University
Phase 3BB
Nivolumab
University of Wisconsin, Madison
Phase 3B

View all 50 →

Same molecule, other indications

Tilmanocept is also rated in:

melanomaDormant
B
Indicative ·
61 / 100
View asset →
Sentinel Lymph Node BiopsyDormant
B
Indicative ·
56 / 100
View asset →
Sentinel Lymph NodeDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →